Evidence Explorer · MS-N283 · Investigational drug repurposing · Appraised November 9, 2026
Adding high-dose hydroxychloroquine to gemcitabine and nab-paclitaxel did not improve the primary one-year survival endpoint in a randomized phase II trial of advanced pancreatic cancer. A higher response rate did not translate into longer survival.
Evidence at a glance
- Population: 112 people with previously untreated metastatic or advanced pancreatic ductal adenocarcinoma.
- Intervention: gemcitabine/nab-paclitaxel with hydroxychloroquine 600 mg twice daily versus chemotherapy alone.
- Primary result: one-year survival 41% versus 49%; median overall survival 11.1 versus 12.1 months and median progression-free survival 5.7 versus 6.4 months.
- Evidence label: randomized negative for the primary survival endpoint; not supported for routine use.
What was studied
The open-label trial randomized 55 participants to hydroxychloroquine and 57 to control. Objective response was higher with hydroxychloroquine (38.2% versus 21.1%), but the prespecified survival endpoint was null.
A separate preoperative study reported stronger pathologic response but no overall- or relapse-free-survival difference. Tumor response, biomarkers and resectability hypotheses require separate confirmation and should not be described as a cure.
What this evidence cannot establish
A response-rate or pathology signal cannot substitute for survival, and results in potentially resectable disease do not establish benefit in metastatic disease. Hydroxychloroquine should not be added outside an appropriate oncology trial.
Safety and practical context
Grade 3–4 neutropenia, fatigue, nausea, neuropathy, visual changes and neuropsychiatric symptoms differed between groups in the advanced-disease trial.
Hydroxychloroquine can prolong QT and cause cardiomyopathy and irreversible retinal toxicity. Risk rises with other QT-prolonging drugs, electrolyte abnormalities, renal impairment, cumulative dose and tamoxifen exposure.
Questions for the care team
- Is the goal response before surgery or longer survival in metastatic disease?
- What evidence supports benefit in this exact setting?
- How will ECG, electrolytes, eye risk and interacting antiemetics or cancer drugs be reviewed?
Sources and identifiers
- Randomized advanced-pancreatic-cancer phase II trial — PMID 31120501
- Randomized preoperative pancreatic-cancer study — PMID 32156749
- Current US hydroxychloroquine prescribing information
Funding and conflicts: The trials were academic studies with institutional and grant support. Full funding and conflict statements should be checked in the primary reports for protocol-level decisions.
Source access and dates: Original reports, registry records and official safety sources available through the links above were checked November 9, 2026. Last literature search November 9, 2026.
Educational evidence summary, not individualized medical advice. Investigational or repurposed products should not replace established cancer treatment. Symptom, biomarker, laboratory or animal findings do not establish tumor control, recurrence prevention or longer survival.
